Genomic signature predicts safety of omitting RT in early breast cancerJune 7, 2021Breast CancerASCO Breast Cancer
ACE inhibitor prevents trastuzumab-associated LVEF decline after anthracyclines in BC treatmentJune 7, 2021Breast CancerPreventive CareASCO Breast Cancer
Pregnancy effect on chemotherapy does not affect maternal breast cancer outcomesJune 7, 2021Breast CancerASCO Breast Cancer
ASCO 2021: Breast cancer sessions not to missJune 4, 2021Breast CancerMetastatic Breast CancerASCO Breast Cancer
'Exciting': Olaparib benefit also in early BRCA+ breast cancer June 4, 2021Breast CancerASCO Breast Cancer
IL-6 levels predict distant breast cancer recurrenceJune 4, 2021Metastatic Breast CancerBreast CancerASCO Breast Cancer
Trastuzumab deruxtecan-related lung disease in MBC patients can occur anytime in first yearJune 2, 2021Metastatic Breast CancerBreast Cancer
Endocrine therapy benefits in premenopausal breast cancer differ by molecular riskMay 26, 2021Breast CancerMetastatic Breast Cancer
New targeted treatments are major advances for HER2-positive breast cancerMay 21, 2021Breast CancerMetastatic Breast Cancer
GELATO trial: Chemoimmunotherapy may help in metastatic invasive lobular breast cancerMay 19, 2021Metastatic Breast CancerBreast Cancer
No survival dip with neoadjuvant letrozole-palbociclib in NeoPAL studyMay 19, 2021Breast CancerMixed Topics
The power and promise of social media in oncologyMay 3, 2021Patient & Survivor CareBreast CancerCNS/Brain CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHead & Neck/Thyroid Cancers
Hyperprogression on immunotherapy: When outcomes are much worseApril 30, 2021ImmunotherapyNonmelanoma Skin CancerMelanomaBreast CancerGastroenterologyGastrointestinal CancerGenitourinary Cancer
